Structure Therapeutics Inc. — Director's Dealing 2023

Feb 9, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Structure Therapeutics Inc. (GPCR)
CIK: 0001888886
Period of Report: 2023-02-07

Reporting Person: FMR LLC (See Remark 1)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-07	Ordinary Shares	C	965115	—	Acquired	965115	Indirect
2023-02-07	Ordinary Shares	C	57523	—	Acquired	57523	Indirect
2023-02-07	Ordinary Shares	C	10154	—	Acquired	67677	Indirect
2023-02-07	Ordinary Shares	C	7411	—	Acquired	75088	Indirect
2023-02-07	Ordinary Shares	C	6947	—	Acquired	82035	Indirect
2023-02-07	Ordinary Shares	C	3572022	—	Acquired	3572022	Indirect
2023-02-07	Ordinary Shares	C	568098	—	Acquired	4140120	Indirect
2023-02-07	Ordinary Shares	C	414621	—	Acquired	4554741	Indirect
2023-02-07	Ordinary Shares	C	214663	—	Acquired	4769404	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-07	Series A Convertible Preferred Shares	$	C	965115	Disposed		Ordinary Shares (965115)	Indirect
2023-02-07	Series A Convertible Preferred Shares	$	C	57523	Disposed		Ordinary Shares (57523)	Indirect
2023-02-07	Series A+ Convertible Preferred Shares	$	C	10154	Disposed		Ordinary Shares (10154)	Indirect
2023-02-07	Series B Convertible Preferred Shares	$	C	7411	Disposed		Ordinary Shares (7411)	Indirect
2023-02-07	Series B-1 Convertible Preferred Shares	$	C	6947	Disposed		Ordinary Shares (6947)	Indirect
2023-02-07	Series A Convertible Preferred Shares	$	C	3572022	Disposed		Ordinary Shares (3572022)	Indirect
2023-02-07	Series A+ Convertible Preferred Shares	$	C	568098	Disposed		Ordinary Shares (568098)	Indirect
2023-02-07	Series B Convertible Preferred Shares	$	C	414621	Disposed		Ordinary Shares (414621)	Indirect
2023-02-07	Series B-1 Convertible Preferred Shares	$	C	214663	Disposed		Ordinary Shares (214663)	Indirect

Footnotes

F1: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.